| 37th week of 2015 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20150250791 | COMBINING SILDENAFIL WITH CAFFEINE IN AN ORAL DISINTEGRATING DOSAGE FORM - Pharmaceutical compositions and formulations are provided herein comprising a phosphodiesterase type 5 inhibitor, such as sildenafil citrate; and, an adenosine receptor (A1, A2A, A2B, and A3 receptors) antagonist, such as caffeine, for (i) treating erectile dysfunction while (ii) inhibiting the lower of the blood pressure, (iii) increasing the bioavailability of the compositions, and (iv) reducing the Tmax in the subject. Methods of making and administering oral disintegrating tablets are also provided. | 2015-09-10 |
| 20150250792 | ALPHA HYDROXY AMIDES - The present invention relates to alpha hydroxy amides including compounds of formula I | 2015-09-10 |
| 20150250793 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO - To compare sensitivities of the compounds, A549 human lung cancer cells were treated with increasing concentrations (0, 1, 5, 10, 25 μM) of 2-(2-Nitro-fluoren-9-ylidenemethyl)-phenol (CYD-1-87) and derivatives for 48 h. The surviving cell fraction was determined using the sulforhodamine B (SRB) assay as described in (Vichai & Kirtikara, Nat Protoc 1, 1112-1116, 2006 hereby incorporated by reference). The sulforhodamine B (SRB) assay is used for cell density determination, based on the measurement of cellular protein content. The method described here has been optimized for the toxicity screening of compounds to adherent cells in a 96-well format. After an incubation period, cell monolayers are fixed with 10% (wt/vol) trichloroacetic acid and stained for 30 min, after which the excess dye is removed by washing repeatedly with 1% (vol/vol) acetic acid. The protein-bound dye is dissolved in 10 mM Tris base solution for OD determination at 510 nm using a microplate reader. The results are typically linear over a 20-fold range of cell numbers. CYD-2-11 has an IC | 2015-09-10 |
| 20150250794 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR - Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases. | 2015-09-10 |
| 20150250795 | sGC STIMULATORS - Compounds of Formula IA and Formula IB are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. | 2015-09-10 |
| 20150250796 | PROCESS FOR MANUFACTURING STERILE BRINZOLAMIDE OPHTHALMIC SUSPENSION - The present invention relates to a process for manufacturing sterile Brinzolamide Ophthalmic Suspension. Specifically, the present invention relates to a process for manufacturing sterile ophthalmic suspension comprising Brinzolamide sterilized by Dry Heat Sterilization and pharmaceutical suspension obtained by using the said sterilized Brinzolamide. The present invention also relates to a process of manufacturing sterile ophthalmic suspension comprising combination of Brinzolamide sterilized by Dry Heat Sterilization and beta blocker. | 2015-09-10 |
| 20150250797 | NUTRACEUTICAL CO-CRYSTAL COMPOSITIONS - Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs. | 2015-09-10 |
| 20150250798 | Methods and Pharmaceutical Compositions For Treating Down Syndrome - The compounds and pharmaceutical compositions of the present invention are believed to significantly inhibit Dyrk1a activity which suggests that the agents could provide therapeutic benefit for Down syndrome, since Dyrk1a overproduction in Down syndrome appears to account for the developmental cognitive impairment and reduction in neurogenesis. The compounds and pharmaceutical compositions, administered during early post-natal development, may increase neurogenesis and thereby reduce cognitive impairment which may ultimately allow individuals with Down syndrome to live a more independent life. | 2015-09-10 |
| 20150250799 | Triazolopyridine Compounds - The invention relates to compounds of formula (I) and salts thereof: | 2015-09-10 |
| 20150250800 | ACUTE TREATMENT OF HEADACHE WITH PHENOTHIAZINE ANTIPSYCHOTICS - Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic. | 2015-09-10 |
| 20150250801 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION - The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject. | 2015-09-10 |
| 20150250803 | USE OF VITAMIN D GLYCOSIDES AND SULFATES FOR TREATMENT OF DISEASE - Methods of treating vitamin D-sensitive diseases without inducing severe forms of hypercalcemia. The methods comprise administering biologically inert vitamin D prodrugs. The vitamin D prodrugs have a vitamin D-drug moiety and a pro moiety, wherein the pro moiety is selected from the group consisting of a glycone moiety and a sulfate moiety. The vitamin D prodrugs are activated by enzymes at target tissues or cells that cleave the pro moiety from the vitamin D drug moiety, freeing the vitamin D-moiety from the pro moiety in the vicinity of the target tissues or cells. The methods of the invention prevent large, acute, systemic increases in the free form of the vitamin D-drug moiety that would otherwise lead to hypercalcemia. The methods can be used to treat hyperproliferative, autoimmune, or infectious diseases throughout the body, including the intestine. Compositions of the vitamin D prodrugs useful in the described methods are also disclosed. | 2015-09-10 |
| 20150250804 | Nitric Oxide Donors - The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria. | 2015-09-10 |
| 20150250805 | COMPOUNDS FOR THE TREATMENT OF ADDICTION - Disclosed are novel compounds having the structure of Formula (I): | 2015-09-10 |
| 20150250806 | DIETARY SUPPLEMENT CONTAINING PHOSPHOLIPID-DHA AND FOLATE - Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid. The manufactured dietary supplement also contains L-methylfolate. | 2015-09-10 |
| 20150250807 | USE OF NON-DIGESTIBLE SACCHARIDES FOR GIVING AN INFANT THE BEST START AFTER BIRTH - A food or supplement for pregnant women comprising water soluble, non-digestible saccharides is described. The composition is used to improve the flora and/or immune system of the pregnant women, to improve the immune system of the infant and to improve the intestinal flora of the infant after birth. | 2015-09-10 |
| 20150250808 | TREATMENT OF AUTOPHAGY-BASED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTIC AND SCREENING ASSAYS AND KITS - In one embodiment, the invention provides a method of treating a subject suffering from a | 2015-09-10 |
| 20150250809 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS - The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role. | 2015-09-10 |
| 20150250810 | D-TAGATOSE-BASED COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ATHEROSCLEROSIS, METABOLIC SYNDROME, AND SYMPTOMS THEREOF - Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes. | 2015-09-10 |
| 20150250811 | PURIFIED LIMONIN GLUCOSIDE FOR PREVENTION AND TREATMENT OF CHRONIC DISEASES - One exemplary embodiment of the disclosure provides methods and compositions for treating a subject suffering from Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, type 2 diabetes, metabolic syndrome, cardiovascular disease, chronic kidney disease, and certain cancers, or a combination thereof, by administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject. In another exemplary embodiment, the disclosure provides methods and compositions for treating a subject suffering from elevated circulating concentrations of liver enzymes wherein the liver enzymes are selected from gamma glutamyl transferase, alanine amino transferase, alkaline phosphatase and complement fraction 3 or a combination thereof, the method comprising administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject wherein the treating results in a decreased circulating concentration of the liver enzymes. | 2015-09-10 |
| 20150250812 | DIETARY SUPPLEMENT CONTAINING PHOSPHOLIPID-DHA AND B VITAMINS - Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid. The manufactured dietary supplement also contains L-methylfolate, vitamin B | 2015-09-10 |
| 20150250813 | DIETARY SUPPLEMENT CONTAINING PHOSPHOLIPID-DHA, FOLATE, AND N-ACETYL-L-CYSTEINE - Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid. The manufactured dietary supplement also contains L-methylfolate, vitamin B | 2015-09-10 |
| 20150250814 | TREATMENT OF DIARRHEA AND POST-WEANING DIARRHEA WITH RESISTANT POTATO STARCH - Low levels of resistant potato starch, for example, 0.5-1.0% of total diet, have a beneficial effect on post-weaning diarrhea, infectious diarrhea and gastrointestinal stresses associated with weaning. Also described are capsules and tablets of resistant potato starch, and methods for making said capsules and tablets. | 2015-09-10 |
| 20150250815 | INDUCTION OF CHRONIC ELEVATION OF INTRAOCULAR PRESSURE WITH INTRACAMERAL CROSS-LINKING HYDROGEL - The present invention provides a method for inducing chronic elevation of intraocular pressure in the eyes of an animal by introducing into the eyes a cross-linking hydrogel, an animal produced by this method, as well as a screening method useful for identifying compounds capable of modulating intraocular pressure as well as for identifying compounds capable of modulating retinal ganglion cell survival and/or regeneration. | 2015-09-10 |
| 20150250816 | METHOD OF TREATING A MAMMALIAN TEAT AND RELATED COMPOSITIONS - A method of treating or protecting a mammalian teat by applying a topical composition to the teat, wherein the topical conditioning composition comprises (a) citrate; (b) methylene blue; and (c) an alkyl para-hydroxybenzoate; as well as related methods and compositions. | 2015-09-10 |
| 20150250817 | Mineral, Nutritional, Cosmetic, Pharmaceutical, And Agricultural Compositions And Methods For Producing The Same - Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil. | 2015-09-10 |
| 20150250818 | Composition and Method of Using Medicament for Treatment of Cancers and Tumors - The composition includes a chemical depilatory that may be used in a method of destroying cancer and/or tumor cells and removing the resulting debris from the body. The composition includes thioglycolate and is directly applied to the cancer and/or tumor target cells to interrupt and disable their functioning. This method is unique because it enables the composition to affect the cancer and/or tumor cells without being transported by a carrier through the body to them. This anti-cancer and anti-tumor treatment not only targets the abnormal cells, but also eradicates the microorganisms in the tissue at the target site, which prevents the abnormal growth from recurring due to the presence of residual microorganisms that may trigger formation of dysplastic cells. | 2015-09-10 |
| 20150250819 | PERITONEAL DIALYSIS FLUID - The present invention is a sterile peritoneal dialysis fluid, including an acidic first liquid containing 60.0 to 94.0 g/L of icodextrin and 0 to 2.34 g/L of sodium chloride, and an alkaline second liquid containing an alkaline pH regulator, in which the first liquid after sterilization has a pH of 5.0 to 5.5, the second liquid after sterilization has a pH of 6.5 to 7.5, and a mixture of the first liquid and the second liquid after sterilization has a pH of 6.0 to 7.5. The present invention can provide a peritoneal dialysis fluid containing icodextrin, in which the stability of icodextrin during the heat sterilization and the subsequent storage can be improved to the maximum, and the pH of the peritoneal dialysis fluid is close to the physiological range. | 2015-09-10 |
| 20150250820 | SUBSTANCE FOR THE TREATMENT OF INFECTIONS - The invention relates to the use of dichloric acids and the derivatives thereof for producing medicaments used for disinfecting body cavities. | 2015-09-10 |
| 20150250821 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 2015-09-10 |
| 20150250822 | PLATELET COMPOSITIONS AND USES THEREOF - The invention generally features isolated platelets, compositions, methods, and kits useful for targeted delivery of one or more therapeutic agents to a site of injury, inflammation, disease, or disorder. Also featured are methods and kits for producing a platelet loaded with one or more therapeutic agents. Platelets loaded with one or more therapeutic agents are useful for treating neoplasia, hemophilia, wounds, and other pathologies or conditions involving sites of injury, inflammation, disease, or disorder where platelets are able to localize. | 2015-09-10 |
| 20150250823 | Preeclamptic Placental Mesenchymal Stem Cell Conditioned Medium for Use in the Treatment of a Tumour - It is described a conditioned medium (CM) obtainable by culturing, in a liquid culture medium, placental mesenchymal stem cells from a preeclamptic placenta. The conditioned medium object of the invention includes at least IP-10 and TARC proteins and it is used for the therapeutic treatment of a tumor, preferably an epithelial tumor. | 2015-09-10 |
| 20150250824 | METHODS AND COMPOSITIONS FOR EXPANSION OF STEM CELLS AND OTHER CELLS - Presented herein are methods of generating a multipotent or immature cell from a mature somatic cell, involving contacting a mature somatic cell with one or more small molecule compounds selected from: a histone deacetylase (HDAC) inhibitor; a glycogen synthase kinase 3 (GSK-3) inhibitor; one or more transforming growth factor-beta receptor (TGF-βR) inhibitors; one or more lysine-specific demethylase 1 (LSD1) inhibitors; a cAMP agonist; a histone lysine methyltransferase (EZH2) inhibitor; and a histone methyltransferase (HMTase) G9a inhibitor; valproic acid. Also provided are methods of generating a multipotent or immature cell from a somatic cell, by driving expression of OCT4, or an OCT4 functional homolog or derivative, under the control of a high expressing promoter. Presented herein are also methods of stem cell expansion, stem cell regeneration and differentiation, which comprise contacting stem cells with one or more small chemical compounds. | 2015-09-10 |
| 20150250825 | DOPAMINERGIC NEURONS DIFFERENTIATED FROM PLURIPOTENT STEM CELLS AND USES THEREOF - The present invention provides populations of neural cells derived from pluripotent cells, and methods for making and using the same. Disclosed herein are methods for generating dopaminergic neurons in vitro using a combination of agents that cause differentiation of the pluripotent cells into dopaminergic neurons. Also disclosed are methods for treating a neurodegenerative disease in a patient by generating dopaminergic neurons in vitro, and transplanting them into the brain of the patient, such that the dopaminergic neurons are sufficient to reduce or eliminate the symptoms of the neurodegenerative disease. | 2015-09-10 |
| 20150250826 | ISOLATION AND CHARACTERIZATION OF MUSCLE REGENERATING CELLS - Cell populations enriched for human myogenic progenitors are obtained by selection on the basis of expression of specific cell surface markers. The muscle progenitor cells are characterized as being CD45−, Mac-1−, GlycophorinA−, CD31− and CD34−, ITGA7hi and CD56 intermediate and methods of use thereof. Methods are provided for the separation and characterization of human myogenic cells, which are precursor cells having the ability to form muscle. The cells are identified and isolated from cells found within the pool of muscle satellite cells, located beneath the basal lamina of mature muscle fibers in the muscle tissue. | 2015-09-10 |
| 20150250827 | BIO-MIMETIC ULTRATHIN HYDROGEL COATINGS FOR PANCREATIC ISLET TRANSPLANTATION - The present disclosure provides multifunctional cytoprotective materials applied to coat living cells or aggregates of cells such as, but not limited to, pancreatic islets. The coating utilizes hydrogen-bonded interactions of a natural polyphenol (tannic acid) with poly(N-vinylpyrrolidone) deposited on the cell aggregate surface via non-ionic layer-by-layer assembly. The coating is conformal over the surface of such as mammalian islets. The coated islets maintain their viability and cell functionality for at least 96 hours in vitro. The coating demonstrates immunomodulatory cytoprotective properties suppressing pro-inflammatory cytokine synthesis in stimulated bone marrow-derived macrophages and diabetogenic BDC-2.5 T cells. The coating material combines high chemical stability under physiologically relevant conditions with capability of suppressing cytokine synthesis, crucial parameters for prolonged islet integrity, viability, and function in vivo. | 2015-09-10 |
| 20150250828 | METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELL SHEET - The present invention provides a method of producing a cell sheet comprising a retinal pigment epithelial cell layer and a vascular forming cell layer composed of stem cells having vascular formation ability or blood vessel constituting cells, comprising a step of laminating the retinal pigment epithelial cell layer and the vascular forming cell layer, and a cell sheet obtained by said method. Furthermore, the present invention provides a cell sheet for transplantation, comprising a cell layer formed with retinal pigment epithelial cells obtained by inducing differentiation of stem cells or progenitor cells ex vivo, a basement membrane secreted from said cells, and a vascular forming cell layer composed of stem cells having vascular formation ability or blood vessel constituting cells. | 2015-09-10 |
| 20150250829 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components, extracts of micronized placental components, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions and the extracts thereof are also described herein. | 2015-09-10 |
| 20150250830 | Novel Preparation for the Treatment of Itching and Inflammation Associated with Psoriasis and Other Topical Skin Maladies - The present invention relates to a novel liquid preparation for the topical treatment for itching and inflammation associated with psoriasis and other common skin maladies wherein a layered mass of organic and inorganic material comprising: 1) Fruits, vegetable by-products, and paper scraps; 2) Grit comprising a blend of crushed volcanic rock; and, 3) A microbial soil enhancer is composted by a population of selected earthworms. The composting mass is misted daily to achieve a uniformly moist consistency. For the first two weeks, any worm tea (runoff) exiting the composting mass after each daily misting is recycled into the next day's misting fluid. A fraction of the worm tea produced during the third through twelfth weeks is harvested, pH adjusted, and treated with surfactant to form the liquid preparation. | 2015-09-10 |
| 20150250831 | METHODS OF TREATING PIGS WITH BACILLUS STRAINS - Disclosed are methods of administering at least two | 2015-09-10 |
| 20150250832 | BACTERIAL COMPOSITION FOR THE TREATMENT OF COLIBACILLOSIS ON FARMS, IN PARTICULAR POULTRY FARMS, AND ALSO DRINKING WATER CONTAINING SUCH A BACTERIAL COMPOSITION - A bacterial composition for the treatment of colibacillosis on farms, in particular poultry farms, contains at least 10 | 2015-09-10 |
| 20150250833 | PROBIOTIC AND PREBIOTIC COMPOSITIONS - The invention relates to products and compositions that may be beneficial in animal husbandry. Said products and compositions comprise microorganisms, such as bacteria, and probiotic bacteria in particular. Thus, provided herein are microbial strains, as well as selection criteria which will enable the skilled reader to find further strains useful in the present invention. The strains, as well as compositions comprising the same, may be administered to animals, farmed animals such as swine in particular. The administration may occur in the first days of life. By administration of the products or compositions of the inventions animal growth can be promoted and animal weight can be increased. Bacterial infections may also be prevented or treated by said compounds or compositions. | 2015-09-10 |
| 20150250834 | NOVEL LACTIC ACID BACTERIA AND ITS APPLICATIONS IN IMMUNOMODULATION AND ANTI-INFLAMMATION - The invention provides a new lactic acid bacteria (LAB) strain with immunomodulatory and anti-inflammatory activity and a composition containing and method using the same. The LAB of the invention can be administrated for modulating an immune response in order to restore or prevent metabolic disorders caused by obesity or chronic inflammation. | 2015-09-10 |
| 20150250835 | COMPOSITION AND METHOD OF LACTOBACILLUS REUTERI GMNL-89 IN TREATING TYPE 2 DIABETES - Present invention features a novel use of | 2015-09-10 |
| 20150250836 | LACTOBACILLUS REUTERI GMNL-263 COMPOSITION FOR CONTROLLING BODY WEIGHT AND ITS USE THEREOF - Present invention features a method for controlling body weight, comprising | 2015-09-10 |
| 20150250837 | ONCOLYTIC VIRUS ENCODING PD-1 BINDING AGENTS AND USES OF THE SAME - The present disclosure concerns the use of oncolytic viruses for the treatment of cancer. In particular, the use of a herpes simplex virus, a vaccinia virus, or an adenovirus containing a gene encoding a PD-1 binding agent, such as a scFv polypeptide, to achieve a particular degree of oncolysis is described. In some embodiments, the oncolytic virus expressing the PD-1 binding agent is effective at inducing immune responses that kill cancer cells at distant sites from the primary tumor. An oncolytic virus can also be engineered to be less toxic or damaging to non-cancer cells by mutation or modification of gene products such that the alterations render the viruses better able to infect the host, less toxic, and/or better able to selectively infect cancer cells. | 2015-09-10 |
| 20150250839 | NUTRITIONAL SUPPLEMENT CONTAINING IRON - A nutritional supplement containing fungal biomass having at least 100 mg/kg iron and processes for producing the nutritional supplement using filamentous fungi are described. | 2015-09-10 |
| 20150250840 | Medicinal Composition of Extract of Seed of Emblica Officinalis and Method of Preparing the Same - A composition having an extract of seed of | 2015-09-10 |
| 20150250841 | METHODS AND COMPOSITIONS TO REDUCE FAT GAIN, PROMOTE WEIGHT LOSS IN ANIMALS - The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels. | 2015-09-10 |
| 20150250842 | COMBINATION AND/OR COMPOSITION COMPRISING BACILLUS, AND YUCCA, QUILLAJA, OR BOTH AND A METHOD FOR USING AND MAKING - The present disclosure concerns embodiments of a combination and/or composition comprising | 2015-09-10 |
| 20150250843 | COMPOSITION CONTAINING A SPIRANTHES SINENSIS EXTRACT AND PHARMACEUTICAL APPLICATIONS THEREOF - The present invention is related to a pharmaceutical composition comprising an effective amount of a | 2015-09-10 |
| 20150250844 | FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, PACLITAXEL, AND ASPIRIN - The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity. | 2015-09-10 |
| 20150250845 | LOW FREQUENCY GLATIRAMER ACETATE THERAPY - A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. | 2015-09-10 |
| 20150250846 | N-ACYLDIPEPTIDE DERIVATIVES AND THEIR USES - N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject. | 2015-09-10 |
| 20150250847 | PEPTIDES FOR SUPPRESSING INFLAMMATION - Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications. | 2015-09-10 |
| 20150250848 | THERAPY AND KIT FOR THE PREVENTION AND TREATMENT OF CYSTIC FIBROSIS - A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis. | 2015-09-10 |
| 20150250849 | COMPOSITIONS AND METHODS FOR TREATING PRURITUS - The present invention encompasses methods and compositions for alleviating pruritus. The compositions may comprise an analgesic agent. | 2015-09-10 |
| 20150250850 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERLIPIDEMIA, FATTY LIVER, ATHEROSCLEROSIS AND OTHER DISORDERS ASSOCIATED WITH METABOLIC SYNDROME - The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a Nuclear Transport Modifier may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease in cholesterol and triglyceride levels in the blood and liver, a decrease in atherosclerotic lesion size, a decrease in body weight and in hyperglycemia, a reduction of fatty liver inflammation, and an improvement in liver function. | 2015-09-10 |
| 20150250851 | PEA-BASED PROTEIN MIXTURE AND USE THEREOF IN A LIQUID NUTRITIONAL COMPOSITION SUITABLE FOR ENTERAL FEEDING - This invention relates to a pea-based protein mixture and use thereof in a liquid nutritional composition, in particular suitable for tube feeding, and further relates to said liquid nutritional composition for providing long-term complete enteral nutrition to patients in need thereof. More specifically, the pea-based protein mixture and the liquid nutritional composition comprising said pea-based protein mixture comprises more than 25 weight % and up to 80 weight % of vegetable protein comprising a source of intact pea protein and a source of intact soy protein. The invention relates further to a method for long-term enteral nutrition of patients in need thereof comprising administering an effective amount of said liquid nutritional composition comprising said pea-based protein mixture, in particular comprising a defined amount of intact pea protein and a second vegetable intact protein, other than pea protein. | 2015-09-10 |
| 20150250852 | METHODS FOR ISOLATION, USE AND ANALYSIS OF FERRITIN - This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include remineralization of plant ferritin protein with iron atoms. | 2015-09-10 |
| 20150250853 | METHODS AND COMPOSITIONS FOR MODIFYING THE IMMUNE RESPONSE - The present invention is directed to methods and compositions for modulating proteins involved in the immune response. The present invention further provides methods and compositions for treatment of autoimmune disease and cancer by modulating the expression and activity of such proteins. | 2015-09-10 |
| 20150250854 | VOLTAGE GATED CALCIUM CHANNEL BETA-SUBUNIT ANCHORING REGULATOR PROTEIN AND USES THEREOF - The present invention relates to a novel gene encoding a protein termed voltage gated calcium channels β subunit anchoring regulator protein (VDCC BARP) or a peptide fragments thereof. The present invention also relates to the use of VDCC BARP in modulation of voltage gated calcium channels via altering the concentration of VDCC BARP or a peptide fragments thereof. | 2015-09-10 |
| 20150250855 | COMPOSITIONS FOR RAPIDLY TREATING SEVERE HYPOGLYCEMIA - Disclosed is a composition for parenteral administration comprising a glucagon peptide which has been dried in a non-volatile glycine buffer, and wherein the glucagon peptide has a pH memory that is about equal to the pH of the glucagon peptide in the non-volatile buffer, wherein the pH memory is between 2.5 to 3.5, an aprotic polar solvent, wherein the peptide is solubilized in the aprotic polar solvent, and wherein the aprotic polar solvent is dimethyl sulfoxide (DMSO), trehalose, glycine, and optionally hydrochloric acid, wherein the moisture content of the composition is less than 5 wt. %. | 2015-09-10 |
| 20150250856 | PHARMACEUTICAL COMPOSITION FOR TRANSMUCOSAL DELIVERY AND METHODS FOR TREATING DIABETES IN A SUBJECT IN NEED THEREOF - The present disclosure relates to pharmaceutical compositions of solid dosage form for intraoral administration that provides effective delivery of insulin and insulin analogs via the transmucosal route. Also provided are methods for treating pre-diabetes, diabetes and metabolic syndrome in a subject in need thereof. | 2015-09-10 |
| 20150250857 | Process for the Preparation of Insulin-Zinc Complexes - The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation. | 2015-09-10 |
| 20150250858 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 - A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin. | 2015-09-10 |
| 20150250859 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND COMPOSITIONS AND MATERIALS THEREFOR - The present invention generally relates to methods, compositions and materials for treatment of and promotion of neurological functional recovery from neurological conditions including central nervous system injuries and/or diseases. | 2015-09-10 |
| 20150250860 | SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF - The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders. | 2015-09-10 |
| 20150250861 | Purification, Characterization, and Use of Clostridium Botulinum Neurotoxin BoNT/A3 - Preparations of | 2015-09-10 |
| 20150250862 | TARGETED EXPANSION OF QA-1-PEPTIDE-SPECIFIC REGULATORY CD8 T CELLS TO AMELIORATE ARTHRITIS - Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection. | 2015-09-10 |
| 20150250863 | Method for Eliciting an Immune Response to Human Telomerase Reverse Transcriptase - The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers. | 2015-09-10 |
| 20150250864 | ANTI-CANCER VACCINES - The present provides tumor-associated antigens and their use as vaccines for treating and limiting cancers in a patient. In specific aspects, HERV type K envelope proteins and peptides are provided. Such proteins and peptides can be used to elicit specific immune responses—both humoral and cellular—that target tumor cells expressing the HERV type K envelope protein. | 2015-09-10 |
| 20150250865 | MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO - The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a | 2015-09-10 |
| 20150250866 | Live Attenuated Antigenically Marked Classical Swine Fever Vaccine - Controlling Classical Swine Fever Virus (CSFV) involves either prophylactic vaccination or non-vaccination and elimination of infected herds depending on the epidemiological situation. Marker vaccines allowing distinction between naturally infected from vaccinated swine could complement “stamping out” measures. Previously, we reported the development of FlagT4v, a double antigenic marker live attenuated CSFV strain. FlagT4v was later shown as not to be completely stable in terms of its attenuation when assessed in a reversion to virulence protocol. We have developed a modified version of the FlagT4v where changes in the codon usage of genomic areas encoding for Flag and T4 were introduced to rectify the reversion to the virulent genotype. The new virus, FlagT4-mFT-Gv, possesses the same amino acid sequence as FlagT4v except for one substitution, Asparagine is replaced by Glycine at position 852 of the CSFV polypeptide. FlagT4-mFT-Gv protected swine against challenge with Brescia virulent virus at 21 days post vaccination. | 2015-09-10 |
| 20150250867 | HPV/CYAA-BASED CHIMERIC PROTEINS AND THEIR USES IN THE INDUCTION OF IMMUNE RESPONSES AGAINST HPV INFECTION AND HPV-INDUCED DISORDERS - The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a | 2015-09-10 |
| 20150250868 | Re-Directed Immunotherapy - The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells. | 2015-09-10 |
| 20150250869 | VIRUS-CONTAINING FORMULATION AND USE THEREOF - The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders. | 2015-09-10 |
| 20150250870 | Compositions for Immunotherapy - The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals suffering from a peanut allergy. The present invention further relates to the use of the present compositions for the treatment of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment for desentizing the immune system of a mammal for an allergen. Specifically, the present invention relates compositions suitable for immunotherapy comprising an allergen, wherein substantially 100% of said allergen in said composition is complexed with aluminum. The allergen, e.g. peanut kernel protein extract, is preferably reduced and alkylated in these compositions. | 2015-09-10 |
| 20150250871 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS - This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen. | 2015-09-10 |
| 20150250872 | VACCINE COMPOSITIONS AND METHODS OF USE - The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties. | 2015-09-10 |
| 20150250873 | COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS - The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glycocorticoid receptive diseases. | 2015-09-10 |
| 20150250874 | ACTIVIN RECEPTOR-LIKE KINASE-1 COMPOSITIONS AND METHODS OF USE - Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ALK-1 antagonists. | 2015-09-10 |
| 20150250875 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES - The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection. | 2015-09-10 |
| 20150250876 | Poloxamer-based Pharmaceutical Compositions for Treating Wounds - Compositions and methods for treating bacterial, fungal, and yeast infections in wounds are disclosed. The disclosed poloxamer-based pharmaceutical composition includes a micronized poloxamer composition base combined with one or more suitable active pharmaceutical ingredients (APIs), such as, antibacterial or antifungal, thereby resulting in a synergistic effect for the APIs. The micronized poloxamer composition within poloxamer-based pharmaceutical composition includes poloxamer 407 and poloxamer 188. Poloxamer-based pharmaceutical composition exhibits a particle size average of about 50 μm, which enhance APIs solubility. Additionally, poloxamer-based pharmaceutical composition can be delivered in a plurality of dosage forms, such as, powders, sprays, ointments, pastes, creams, lotions, solutions, and patches, among others. | 2015-09-10 |
| 20150250877 | PATCH - A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer. | 2015-09-10 |
| 20150250878 | NOVEL ANTIFUNGAL COMPOSITION - There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a antifungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-free | 2015-09-10 |
| 20150250879 | TEST FOR HEMOLYTIC POTENTIAL OF PHARMACEUTICAL PRODUCTS AND FORMULATIONS FOR RISK MINIMIZATION - A non-hemolytic acidic composition comprising an immunoglobulin selected from immunoglobulin A, immunoglobulin G or immunoglobulin M at a pH value in the range of 4.65 to 5.7 comprising one or more excipients selected from amino acids, sugars and sugar alcohols in a concentration range of 100-350 mmol/l, in particular 200-350 mmol/l, characterized in that it displays an optical density (OD) in the range of 0.14 to −0.1 when the OD is determined in a spectrophotometer at 414 nm at a film thickness of 0.825 mm; and its use in an assay for determination of the hemolytic potential of intravenously applied pharmaceuticals and compositions and preparations displaying a reduced potential of hemolysis when being applied intravenously. | 2015-09-10 |
| 20150250880 | HYDROGEL-FORMING MATERIAL, PREMIX, AND HYDROGEL FORMATION METHOD - A hydrogel-forming material, a premix, and a method for forming a hydrogel through a simple process at room temperature. The material including: a disperse phase (A) including a lipid peptide-based gelator including at least one of a compound of Formula (1) or pharmaceutically usable salt thereof, water, and a fatty acid salt; and a phase (B) that includes a water-soluble acidic polymer: | 2015-09-10 |
| 20150250881 | Multicomponent Degradable Cationic Polymers - Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine. | 2015-09-10 |
| 20150250882 | Fatty Acid Acylated Amino Acids for Growth Hormone Delivery - The present invention relates to growth hormone compositions comprising a fatty acid acylated amino acids (FA-aa's), which may be used in pharmaceutical compositions such as pharmaceutical compositions for oral administration of growth hormone. | 2015-09-10 |
| 20150250883 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS - Media compositions and methods of enhancing binding of cells to an integrin-binding ligand comprising treating integrin-expressing hematopoietic stem cells ex vivo with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells ex vivo with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells with minimal exposure agonist compounds to a mammal requiring stem cell transplantation in the management of hematologic cancers and genetic diseases. | 2015-09-10 |
| 20150250884 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY - One aspect of the invention relates to AI-helper compositions comprising an AI compound (e.g., melatonin, alpha-lipoic acid, vitamin E, vitamin D, glutathione, resveratrol, astaxanthin, beta carotene, vitamin A, vitamin C, vitamin B12, vitamin B6, folic acid, and taurine) and one or more helper esters. The AI-helper compositions disclosed herein can be used for effective transdermal delivery of the AI compound to a subject. Another aspect of the invention relates to applications and preparations of the AI-helper compositions. | 2015-09-10 |
| 20150250885 | SOLID COMPOSITION COMPRISING IRON FOR USE IN IRON DEFICIENT CONDITIONS - An iron-based composition is described. The composition can be used in conditions of total or relative iron deficiency. In particular, a solid composition is described, preferably in the form of powder or granules, for use in the treatment of disorders or diseases related to or derived from an iron deficiency. The composition is suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly. Finally, a process for preparing the solid composition is also described. | 2015-09-10 |
| 20150250887 | METHOD OF PREPARING RESIN TINCTURES - Described herein are methods for making a pharmaceutical composition for topical, transdermal or transmucosal delivery of a pharmaceutically active agent comprising combining (i) a first composition comprising or consisting of a pharmaceutically active agent and, optionally, a first volatile solvent and/or water, and (ii) a second composition comprising a resin, a second volatile solvent and 10-40% v/v water. Compositions made by these methods also are described, as are compositions comprising a pharmaceutically active agent, a volatile solvent, a resin and 10-40% (w/v) water, and containers containing such compositions or components thereof. | 2015-09-10 |
| 20150250888 | PROCESS FOR PREPARING AQUEOUS DISPERSIONS - The invention discloses a process for preparing aqueous dispersions comprising the components (a) and (b) and optionally (c) or (d) or both, (a) a copolymer consisting of free-radical-polymerized C1- to C4-esters of acrylic or methacrylic acid and alkyl(meth)acrylate monomers with tertiary ammonium groups in the alkyl side groups, (b) 5 to 25% by weight, based on (a), of a C | 2015-09-10 |
| 20150250889 | HEAT-SENSITIVE AMPHIPHILIC POLYURETHANE AND AQUEOUS SOLUTION CAPABLE OF BEING INJECTED BASED ON SUCH MATERIAL - A heat-sensitive sol-gel composition capable of being injected is described, composed of an aqueous solution of at least one amphiphilic polyurethane. | 2015-09-10 |
| 20150250890 | METHOD FOR PREPARING IN SITU-FORMED HYDROGEL USING ENZYME-IMMOBILIZED SUPPORT, AND BIOMEDICAL USE THEREOF - The present invention relates to a method for preparing a hydrogel, comprising the steps of: preparing an enzyme-immobilized support; making contacting with a polymer having a phenol or aniline functional group at a side change and the support in the presence of hydrogen peroxide to cross-link the same; and obtaining a hydrogel by separating the enzyme-immobilized support. | 2015-09-10 |
| 20150250891 | HYALURONIC ACID-BASED DRUG DELIVERY SYSTEMS - The present invention relates to novel hyaluronic acid (HA) hydrogels comprising vesicles loaded with a drug or a protein or a nucleic acid. The new HA hydrogels provide sustain release formulations that are useful for several clinical and surgical applications, including but not limited to ophthalmology (e.g. glaucoma, corneal, ocular inflammatory, vitreoretinal and medical retinal diseases) and dermatological conditions. | 2015-09-10 |
| 20150250892 | BIODEGRADABLE POLYMERIC BUFFERS - Biodegradable pH altering polymers are disclosed. In accordance with certain aspects, the biodegradable pH altering polymers may be used to alter the pH of a microenvironment. In accordance with other aspects, the biodegradable pH altering polymers are utilized for targeted drug and gene delivery and their spontaneous release in intracellular sites of interest. | 2015-09-10 |
| 20150250893 | WEAKLY ACIDIC pH-RESPONSIVE PEPTIDE AND LIPOSOME CONTAINING SAME - A problem to be solved by the present invention is to provide a peptide compound for producing a drug delivery carrier capable of releasing a target substance in a weakly acidic pH environment. The present invention provides a peptide compound comprising a hydrophilic amino acid block and a hydrophobic amino acid block; [1] the peptide compound containing 24 to 36 amino acids in total; [2] the hydrophilic amino acid block containing 4 to 10 amino acids in total and having an average hydropathy index of −3.0 to −1.0; and [3] the hydrophobic amino acid block containing 20 to 32 amino acids in total, containing one or more His residues, and having an average hydropathy index of 1.0 to 2.5. | 2015-09-10 |
